Tag: AMW GmbH

9. November 2021

AMW and AdhexPharma announce strategic partnership for transdermal delivery systems

Today a strategic partnership between AMW GmbH and AdhexPharma SAS on AMW’s transdermal delivery systems technology platform and product portfolio was announced, combining the strengths of both companies in the field of TDS. Under the partnership, AMW will focus on development, marketing authorization and licensing of novel transdermal delivery systems. AdhexPharma will focus on the commercial manufacturing and lifecycle management of the products. AdhexPharma will take over the manufacturing equipment and the IP for AMW’s products Buprenorphine and Rivastigmine and following a transition phase of up to 30 months the contract manufacturing of these Products from AMW.

19. October 2021

AMW signs License and Supply Agreement for Commercialization of its Goserelin and Leuprorelin implants in Israel

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announced that it has entered into license and supply agreements (LSA) with an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in the country of Israel.

26. December 2019

AMW GmbH from Warngau continues to grow and founds an advisory board

Meanwhile more than 100 employees are employed at the pharmaceutical companyin Warngau. The specialy pharmaceuticalwas able to develop a generic drug for the contraception ring Nuvaring of MSD to market maturityin addition to the implants Goserelin and Leuprorelin as well as patches Buprenorphin and Rivastigmin,. With this product, AMW is setting new standards in contraception. Furthermorenew products are under development. In order to position itself even better scientifically and technically, AMW founds an advisory board consisting of Dr. Georg Ingram, Dr. Dirk Schrader and Prof. Dr. Gerhard Winter.